Multiple myeloma (MM) is characterized by the impaired osteogenic differentiation of human mesenchymal stromal cells (hMSCs). Canonical Wnt signaling is critical for the regulation of bone formation, however, recent evidence suggests that the non-canonical Wnt agonist Wnt5a stimulates human osteoblastogenesis through its co-receptor Ror2. The effects of MM cells on non-canonical Wnt signaling and the effect of the activation of this pathway on MM-induced osteoblast exhaustion are not known and were investigated in this study. We found that the osteogenic differentiation of bone marrow hMSCs toward osteoprogenitor cells (PreOB) significantly increased Ror2 expression, and that MM cells inhibit Ror2 expression by PreOB in co-culture by inhibiting the non-canonical Wnt5a signaling. The activation of the non-canonical Wnt pathway in hMSCs by means of Wnt5a treatment and the overexpression of Wnt5 or Ror2 by lentiviral vectors increased the osteogenic differentiation of hMSCs and blunted the inhibitory effect of MM in co-culture. Consistently, Wnt5a inhibition by specific small interfering RNA reduced the hMSC expression of osteogenic markers. Our findings demonstrate that the Wnt5a/Ror2 pathway is involved in the pathophysiology of MM-induced bone disease and that the activation of the non-canonical Wnt5a/Ror2 pathway in hMSCs increases osteogenic differentiation and may counterbalance the inhibitory effect of MM cells.
INTRODUCTION
Multiple myeloma (MM) is characterized by the presence of osteolytic bone lesions because of a severe imbalance in bone remodeling. 1, 2 The osteogenic differentiation of human mesenchymal stromal cells (hMSCs) is typically impaired in MM patients and leads to osteoblast deficiency. [2] [3] [4] Both in vitro and in vivo evidences indicated that the canonical Wnt signaling pathway is critical for the regulation of bone formation. [5] [6] [7] In MM mouse model, its activation leads to bone mass improvement by reducing the development of osteolytic lesions. [8] [9] [10] Specifically, C57BL/KaLwRij mice were inoculated i.v. with murine 5TGM1 cells, resulting in tumor growth in bone and development of MM bone disease; activated Wnt signaling in osteoblasts by treatment with lithium chloride inhibited myeloma bone disease and decreased tumor burden in bone. 8 Other in vivo mouse models were used to evaluate the role of osteoblastic cells in the development of osteolytic lesions such as SCID-hu mice, showing that stimulation of osteoblastic cells reduced in vitro MM cell growth in the presence of osteoclasts 11 and blocking of DKK-1 increased bone formation and bone mass. 12 Finally, it has also been demonstrated that the expression of the DKK-1 inhibitor of the canonical Wnt pathway correlates with the presence of focal bone lesions in MM patients. 13, 14 However, our previous in vitro data indicate that MM cells inhibit canonical Wnt signaling in murine pluripotential mesenchymal cells but not in bone marrow (BM) hMSCs 15 and, in line with this, canonical Wnt signaling was not deregulated in the bone microenvironment of MM patients. 15 Furthermore, it has recently been shown that the activation of the canonical Wnt pathway by Wnt3a in hMSCs stimulates cell proliferation and inhibits osteogenic differentiation in vitro. 16, 17 Together with canonical Wnt signaling, a non-canonical Wnt pathway has been identified that is not dependent on b-catenin activation. Non-canonical Wnt signaling by Wnt5a is transduced through frizzled (FZD) receptors and the Ror2 co-receptor to various cascades, including the disheveled pathways involving the Rho family of small GTPase, JNK and Rho-associated kinase (ROCK). Wnt5a can also trigger intracellular calcium flux, which can lead to the activation of phospho-protein kinase C (P-PKC), calciumdependent molecules such as calmodulin-dependent protein kinase II or calcineurin, and the nuclear factor of activated T cells (NFATc1). [18] [19] [20] Interestingly, recent evidence suggests that, unlike canonical activation by Wnt3a, non-canonical activation by Wnt5a or Wnt4, stimulates the osteogenic properties of BM hMSCs and other sources. 24 It has also been demonstrated that the pro-osteoblastogenic effects of Wnt5a occur through the activation of its co-receptor Ror2, [25] [26] [27] and the critical role of Ror2 in osteoblastogenesis has been recently demonstrated in vitro and in vivo. 28, 29 In this study we investigated the still unknown effects of MM cells on the non-canonical Wnt pathway, and the effects of the activation of this pathway in hMSCs on the impaired osteogenic differentiation induced by MM cells.
MATERIALS AND METHODS Reagents
Recombinant murine (rm) Wnt3a and Wnt5a were obtained from R&D System (Minneapolis, MN, USA); dexamethasone (Dex), ascorbic acid and beta-glycerophosphate were purchased from Sigma-Aldrich (St Louis, MO, USA); RPMI 1640, a-MEM (a-modified essential medium), Dulbecco modified Eagle's medium and culture media with glutamine, penicillin, streptomycin and fetal bovine serum were purchased from Invitrogen Life Technologies (Milan, Italy).
Cell purification and cell-culture conditions Cell lines. The human myeloma cell lines (HMCLs) KMS12 and KMS27
were a kind gift from Dr A Neri (IRCCS, Milan, Italy), whereas the XG-1 cells came from Dr M Amiot (INSERM, Nantes, France). The JJN3 cells were obtained from the DMSZ (Braunschweig, Germany), and the HS-5 human stromal cell line from the American Type Culture Collection (Rockville, MD, USA). The pre-osteocytic cell line hOB-01 was a kind gift from Dr Julia Billiard (Collegeville, PA, USA).
Purification of primary CD138
þ BM cells from MM patients and controls. Primary CD138 þ cells were isolated from mononuclear cells obtained from BM aspirates of 40 consecutive newly diagnosed or relapsed MM patients, 7 patients with monoclonal gammopathy of uncertain significance (MGUS) and 2 healthy donors underwent to surgery. CD138 þ normal plasma cells (PCs) cells were also purified from three tonsils of subjects who underwent tonsillectomy for non-neoplastic diseases. Informed consent was obtained in accordance with the Declaration of Helsinki, and approval was obtained from the Institutional Review Board of the University Hospital of Parma. All of the MM patients underwent total body radiography to identify the presence of osteolytic bone lesions. Patient characteristics are summarized in Supplementary  Table S1 .
The CD138 þ MM cells were purified immunomagnetically using anti-CD138 monoclonal antibody-coated magnetic microbeads (MACS, Miltenyi Biotec, Bergisch-Gladbach, Germany). Samples with a purity of more than 90% via flow cytometry (BD biosciences, San Josè , CA, USA) were analyzed. These samples were evaluated immediately after purification.
Primary hMSCs and osteoprogenitor (preOB) cell cultures. Primary hMSCs were obtained from the CD138 À fraction of BM mononuclear cells taken either from MM patients (10 cases) or healthy donors-including matching subjects for sex and age-who underwent orthopedic or heart surgery without neoplastic disease (10 cases), incubated in a-MEM medium supplemented with 15% fetal bovine serum and 2 mM of glutamine until confluence, and then analyzed at the first passage. To induce the osteoblast phenotype of the hMSCs towards preOB cells, we incubated BM mononuclear cells in the presence or absence of osteogenic differentiating a-MEM medium supplemented with 15% fetal bovine serum and 2 mM of glutamine in the presence of ascorbic acid (50 mg/ml) and Dex (10 À 8 M) for 2 weeks.
Wnt5a treatment of BM mesenchymal stromal cells. Confluent HS-5 stromal cells were treated with increasing doses of rmWnt5a (R&D system) (100-500 ng/ml) for 20 min at 37 1C (in order to evaluate intracellular calcium-influx) using the fluorescent calcium indicator Fluo-4AM (Molecular Probes, Invitrogen) and flow cytometry (BD biosciences), or for 2 h in order to evaluate the effect on NFATc1 and ROCK activity.
To evaluate the effects of Wnt5a on osteogenic differentiation, BM mononuclear cells were seeded in osteogenic differentiation medium in the presence of rmWnt5a (500 ng/ml) or rmWnt3a (500 ng/ml) or vehicle for 2-3 weeks, and the presence of early PreOB cells such as alkaline phosphatase (ALP) þ colony-forming unit-fibroblasts (CFU-F), and the formation of bone nodules was recorded.
Wnt5a and Ror2 overexpression by lentiviral vectors in BM stromal cell lines and primary hMSCs. Wnt5a and Ror2 expression was enforced by specific lentiviral GFP vectors in the HS-5, hMSC and PreOB cell lines. The empty vector pWPI was used as control. Plasmids encoding both Wnt5a and Ror2 cDNA were used to obtain the vectors. The amplified cDNA sequence of Wnt5a/Ror2 was cloned in a lentiviral vector pWPI. The recombinant lentiviruses were obtained by transiently transfecting 293T cells, then concentrated by means of ultracentrifugation at 26 000 r.p.m. for 90 min at 4 1C. The cells were infected with lentiviral GFP vectors encoding the cDNA sequence of Wnt5a or Ror2 or pWPI. After 12-24 h, the efficiency of cell transduction was evaluated by quantifying GFP fluorescence by means of flow cytometry, and its efficacy was evaluated by means of realtime PCR and western blotting.
Small interfering RNA (siRNA) transfection. Wnt5a in hMSCs and PreOB cells was silenced using specific siRNA (Dharmacon, ThermoScientific, Lafayette, CO, USA). Cells were electroporated with 2 nM of Wnt5a siRNA or non-specific siRNA using a one-target protocol and the Gene Pulser System (Bio-Rad Laboratoires Inc., Herculex, CA, USA). After 24-48 h, mRNA and proteins were extracted for the evaluation of osteogenic marker expression.
Co-cultures. Confluent, adherent primary hMSC or PreOB or hOB-01 osteoblastic cells were co-cultured with JJN3 or XG-1 or KMS12 or KMS27 HMCLs or freshly purified MM CD138 þ cells added directly or placed in a transwell insert (pore size 0.4 mM; Corning, Life Sciences, Amsterdam, The Netherlands) for 24-48 h. In some long-term (2-3 weeks) experiments, primary human BM mononuclear cells were co-cultured with HMCLs placed in a transwell insert in the presence or absence of rmWnt5a (500 mg/ml) or rmWnt3a (500 mg/ml) in osteogenic differentiation medium.
Transduced hMSCs were cultured with Wnt5a or Ror2 and HMCLs in osteogenic differentiation medium in the presence or absence of a transwell insert in short-term (48-72 h) co-cultures to evaluate osteogenic markers and long-term (2-3 weeks) co-cultures to evaluate ALP staining and bone nodule formation.
ALP and bone nodule assays. ALP and bone nodule formation in primary hMSCs were assayed for 2 and 3 weeks, respectively. Primary hMSC were incubated in osteogenic differentiation medium in order to obtain PreOB cells under the different experimental conditions, and in hMSCs transduced with lentiviral vectors (pWPI, Wnt5a and Ror2) and differentiated towards PreOB cells for 2-3 weeks.
For the ALP assay, the cells after 2 weeks were fixed with cold formalin at 4 1C, washed three times with PBS, and stained with a semi-quantitative ALP histochemical kit (Sigma-Aldrich, Milan, Italy) in accordance with the manufacturer's procedures. The ALP staining was quantified using ID image analysis software (Kodak Digital Science, Rochester, NY, USA). For the evaluation of bone nodule formation, the cells after 3 weeks were fixed with a 1:1 mixture (vol/vol) of 37% formaldehyde and ethanol for 5 min, washed three times with PBS, and stained for 10 min with a 2% solution of alizarin red, pH 4.2 (Sigma-Aldrich). The nodules were quantified by means of directly counting all of the alizarin red-stained nodules under light microscopy.
RNA isolation and reverse-transcriptase polymerase chain reaction (RT-PCR) amplification Total RNA was extracted from the cells using the RNeasy total RNA isolation kit (Qiagen, Valencia, CA, USA), and then quantified using a Nanodrop ND-100 (Celbio SpA, Milan, Italy). One microgram of RNA was reverse transcribed with 400 U Moloney murine leukemia reversetranscriptase (Applied Biosciences, Life Sciences, Carlsbad, CA, USA) in accordance with the manufacturer's protocol. The cDNAs were amplified by means of PCR using the following specific primer pairs: WNT5a Real-time PCR and PCR array Real-time PCR was performed using the TaqMan Gene Expression Assay (Applied Biosystems) for the following genes: WNT5A: Hs00998537_m1, WNT11: Hs00182986_m1, WNT4: Hs01573504_m1, ROR2: Hs00171695_m1, FZD5: Hs00361869_g1, ALP: Hs00758162_m1, COL1A1: Hs01076777_m1, and ABL Hs01104728_m1. The PCR amplifications were performed in duplicate wells in an iCycler iQ Real-Time Detection System (Bio-Rad, Milan, Italy). Using the endogenous reference gene ABL, the comparative Ct method was applied to normalize the differences in the quantity and quality of RNA, and mRNA was quantified using the comparative DCt method (DCt ¼ mean Ct gene À mean Ct ABL); DDCt was evaluated as the difference between the DCt of a sample and the DCt of the control. The fold-change in mRNA expression was calculated as 2 À DDCt . For the PCR array, 1 mg of total RNA was reverse transcribed using RT2 First Stand Kit (Qiagen), and cDNA was directly added to PCR Master mix containing SYBR green. The mixtures were then aliquoted into 96-well PCR array plates, which profile the expression of 84 Wnt signaling-specific genes (PAHS-043; SA Biosciences, Qiagen). Thermal cycling was done in accordance with the manufacturer's protocol, and the fold-change in expression was assessed by means of DDCt.
Western blotting
Nuclear and cytosolic extracts were obtained from the cells and evaluated by western blotting as previously described. 3 The nuclear extracts were prepared using the Nuclear Extraction Kit (Active Motif, Carlsbad, CA, USA), and tested using the following primary antibodies: anti-total-b-catenin (1:1000) (Chemicon International, Temecula, CA, USA), anti-active-antiPhospho-PKC (1:1000) (Cell Signaling Technology, Euroclone, Milan, Italy), anti-human Ror2 (1:200) (R&D System Inc.), anti-Wnt5a (1:1000) and anticalcineurin (1:1000) (Cell Signaling Technology). Anti-b-actin (1:5000) (Sigma-Aldrich, Inc.) and anti-histone H1 antibodies (1:500) (Upstate, Lake Placid, NY, USA) were, respectively, used as internal controls for cytosol and nuclear proteins. The secondary antibodies were peroxidase conjugated, anti-rabbit, (Chemicon), anti-goat, (Rockland Immunochemicals, Gilbertsville, PA, USA) and anti-mouse antibodies (BD Pharmingen, Franklin Lakes, NJ, USA). Chemiluminescence was detected after immunoblotting by incubating the membranes for 5 min with luminol solution (ECL Plus Western Blotting Detection System, GE Healthcare Amersham, Milan, Italy). The immunoreactive bands were visualized using an exposure time of five minutes (Kodak X-OMAT) and quantified by the Image J software (http://rsbweb.nih.gov/ij/). NFATc1, ROCK and JNK assays.
NFATc1, ROCK and JNK activity were, respectively, evaluated by means of an ELISA-based method (Trans AM NFATc1, Active Motif, Vinci Biochem, Vinci, Firenze, Italy), using commercially available kits (Rock Activity Assay Kit, Cell Biolabs, Inc., San Diego, CA, USA), and FACE JNK (Active Motif), all used in accordance with the manufacturers' procedures.
RESULTS

Expression of non-canonical WNT signaling molecules by hMSCs: effect of osteogenic differentiation
The expression of non-canonical Wnt-related molecules by BM hMSCs and PreOB cells obtained from both MM patients and healthy controls was assessed with oligonucleotide arrays. Both cell types expressed the activator of non-canonical Wnt pathways WNT5A, but lacked the main activators of canonical Wnt signaling (WNT1, WNT3A and WNT8); on the other hand, both expressed the canonical inhibitor DKK-1 and the receptor LRP5 and LRP6 (Table 1) . Ror2 co-receptors and FZD receptors (FZD2, FZD3 and FZD5) were also detected in both cell types ( Table 1) .
The osteogenic differentiation of hMSC towards preOB upregulated Ror2, FZD5 and the canonical inhibitor FRZB, but not WNT5A mRNA expression (Table 1 and Figure 1a ). The stimulatory effect of osteogenic differentiation on Ror2 expression was also demonstrated at the protein level by means of western blotting (Figure 1b) .
The modulation of all these Wnt-related genes by the osteogenic differentiation process was observed in the samples obtained from MM patients as well as healthy controls (Table 1) . Interestingly, the comparison of the mRNA expression of the Wntrelated molecules between healthy donors and MM patients shows that ROR2 mRNA in both hMSCs and PreOB was downregulated in MM patients as compared with healthy controls (Table 1) . Among the remaining Wnt-related genes evaluated herein, we observed a significant upregulation of DKK-1 mRNA in MM samples in comparison with healthy controls in both hMSC and PreOBs (Table 1) .
Expression of non-canonical WNT signaling molecules by HMCLs and CD138
þ MM cells
The expression of Wnt5a and its receptors was also evaluated in several HMCLs as well as in purified CD138 þ cells from a cohort of MM patients, MGUS and control subjects (Figures 1c-e and  Supplementary Table S1 ). PCR demonstrated that JJN3 and XG-1 cells did not express WNT5A mRNA, whereas the KMS12 and KMS27 did. However, WNT5A mRNA levels were lower in the CD138 þ MM cells compared with hMSCs and PreOB cells (Figure 1c) . The presence of Wnt5a protein was only demonstrated in KMS27 cells by means of western blotting, which had sensitivity around 50-100 ng (Figure 1e ). JJN3 cells significantly expressed the Ror2 co-receptors (Figures 1c and 1d) , and all of the HMCLs tested were positive for FZD5 mRNA.
The CD138 þ cells of 27 of the 40 analyzed MM patients (67.5%) expressed WNT5A mRNA, and western blotting demonstrated Wnt5a protein expression in 7 out of 28 cases (25%). There was no significant relationship between the presence or absence of WNT5A mRNA transcript or WNT5A mRNA levels (DCt) and the disease state (diagnosis or relapse), prognostic staging (ISS), or the radiographic presence or absence of osteolytic bone lesions (P ¼ NS) (Supplementary Table S1 ). The median WNT5A mRNA levels in CD138 þ of MM patients were significantly higher than those of normal PC (median À DCt: 0.1 vs À 4.4, P ¼ 0.04) (Figure 1d ), whereas the difference between MM and MGUS patients did not reach statistical significance (median À DCt: 0.1 vs À 3, P ¼ 0.14) (Figure 1d ). ROR2 mRNA levels were significantly higher in CD138 þ MM cells than normal PC (Po0.0001), but not than CD138 þ MGUS cells (P ¼ 0.33) (Figure 1d ). Finally, FZD5 mRNA levels were higher in MM patients as compared with both MGUS patients and normal PC (Po0.0001) (Figure 1d ).
HMCLs and primary CD138
þ MM cells inhibit Ror2/FZD5 expression and the non-canonical Wnt signaling pathway in human BM PreOB cells (PreOBs) To investigate whether MM cells affect the non-canonical Wnt5a pathway in osteprogenitor cells, we co-cultured PreOB cells or the osteogenic cell line HOB-01 with the JJN3, XG-1, KMS27 or KMS12, or purified CD138 þ MM cells, in the presence or absence of a transwell insert for 24-48 h. In these co-culture systems, HMCLs and primary CD138 þ MM cells reduced ROR2 mRNA expression in co-cultured PreOB cells in the presence or absence of a transwell insert after 24 h (as shown for XG-1 in Figure 2a ). This effect was observed with PreOB obtained either from MM patients or from healthy controls. The level of FZD5 mRNA also decreased in cocultured XG-1 and PreOB cells in the presence of a transwell insert but, in the cell-to-cell contact co-cultures the level of FZD5 mRNA increased likely due to the high expression of FZD5 in XG-1 cells (Figure 2a) . The inhibitory effect of XG-1 on Ror2 expression in PreOB cells was confirmed at the protein level (Figure 2b ) after 48 h of co-culture. Similarly, other cell lines such as JJN3 inhibited Ror2 protein expression in HOB-01 cells (Figure 2b) in the presence or absence of a transwell insert. In addition to inhibiting Ror2, the HMCLs decreased the active form of PKC (P-PKC) in HOB-01 cells (Figure 2c) . Interestingly, the inhibitory effect of HMCLs on P-PKC expression in PreOB cells was independent of the production of Wnt5a by HMCLs cells because this effect was observed in both Wnt5a-negative cells such as XG-1 and Wnt5a þ cells such as KMS27 (Figure 2c ). Similarly we found that purified PCs from primary MM tumors inhibit P-PKC in both PreOB and HOB-01 with a more pronounced effect in HOB-01 (Figure 2d ).
In line with the Ror2 and P-PKC inhibition, we found that HMCLs and primary CD138
þ MM cells reduced activated p-JNK in cocultured PreOB cells (data not shown) as well as NFATc1 activity as shown for XG-1 and two representative MM patients in Figure 2e . Finally, HMCLs also had an inhibitory effect on ROCK activity in co-cultured PreOB cells, as shown for XG-1 (Figure 2f ).
Activation of the non-canonical Wnt pathway with Wnt5a treatment increases human BM osteoblastogenesis and reduces the inhibitory effect of both HMCLs and primary CD138
þ MM cells in long-term co-cultures We first evaluated the capacity of Wnt5a treatment to activate the non-canonical signaling pathway in vitro using the human BM stromal cell line HS-5. Stimulation of HS-5 cells with rmWnt5a (100-500 ng/ml) for 20 min at 37 1C led to a dose-dependent increase in Ca þ þ influx, as evaluated by means of a 4-Fluo AM assay (Figure 3a) , which was significant effect at the highest concentration (500 ng/ml). In line with this observation we found that Wnt5a treatment increased P-PKC and calcineurin expression (Figure 3b) . Consequently, increased NFATc1 and ROCK activity was observed in HS-5 cells upon treatment with Wnt5a 500 ng/ml (Figure 3c ).
The effect of Wnt5a treatment on the osteogenic differentiation of BM cells was evaluated by measuring CFU-F and bone nodule formation in long-term cultures. Stimulation with rmWnt5a (500 ng/ml) increased ALP þ CFU-F levels and bone nodule formation in BM mononuclear cells as compared with non-treated controls, whereas Wnt3a (500 ng/ml) did not have this effect (Figure 3d) .
To investigate whether the activation of the non-canonical pathway can revert the inhibitory effect of MM cells on osteoblastogenesis, CFU-F levels and bone nodule formation were evaluated in long-term co-cultures of BM mononuclear cells and either XG-1 or CD138
þ MM cells maintained in osteogenic differentiation medium, with or without canonical (Wnt3a) and non-canonical Wnt molecules (Wnt5a). Wnt5a (but not Wnt3a) treatment blunted the inhibitory effect of HMCLs on the CFU-F (Figure 3e ) and bone nodule formation (Figure 3f 
ROR2
Healthy hMSC À 0.58 Non-canonical Wnt5a signaling in myeloma bone microenvironment M Bolzoni et al control. The efficiency of cell transduction was evaluated by flow cytometry, and was consistently 90% or more (Figure 4a ). The efficacy of Wnt5 transduction at the mRNA level was evaluated by real-time PCR, and demonstrated significantly higher Wnt5a mRNA levels in the Wnt5-transfected HS-5 and hMSC cells as compared with those transfected with the control vector pWPI (Figure 4b) . Wnt5a overexpression was also demonstrated at the protein level in the 48-h conditioned media of the transduced cells ( Figure 4c ). As a result of the Wnt5 overproduction, there was an increased level of active P-PKC and a reduced level of total b-catenin (Figure 4d ), as well as upregulation of cytoplasmic ROCK and nuclear NFTAc1 activities (Figure 4e ). These findings suggest that the overexpression of Wnt5a in mesenchymal stromal cells induces the non-canonical Wnt pathway and inhibits the canonical pathway. The effect of Wnt5a overexpression in hMSCs on osteogenic differentiation was investigated by plating transduced hMSCs in osteogenic differentiation medium for 2-3 weeks. ALP staining and bone nodule formation (detected by means of alizarin red staining) were greater in the primary PreOB cells overexpressing Wnt5a (PreOB-Wnt5a) than in those transduced with the control vector pWPI (PreOB-pWPI) (Figure 4f ). Consistent with this, mRNA expression of the osteogenic markers ALP and COL1A1 was upregulated in PreOB-Wnt5a in comparison with PreOB-pWPI, as shown by qualitative (Figure 4g ) and real-time PCR (Figure 4h) .
Finally, in order to investigate whether Wnt5a overexpression can revert the inhibitory effects of HMCLs on the expression of osteogenic markers in co-culture, we created co-culture systems using PreOB-Wnt5a or PreOB-pWPI cells and XG-1 cells in the absence and presence of a transwell insert. The presence of XG-1 in the co-cultures with PreOB-Wnt5a cells did not inhibit ALP or COL1A1 mRNA levels regardless of the absence or presence of a transwell insert in comparison with the control PreOB-pWPI cells. In all cases, ALP mRNA levels increased and COL1A1 mRNA levels remained unchanged (Figure 4h) .
To confirm the potential role of Wnt5a as a target in regulating the osteogenic properties of hMSCs, we silenced Wnt5a with a specific siRNA in both hMSCs and PreOB cells. There was a significant reduction in Wnt5a transcript levels after 24 h in the cells treated with specific anti-Wnt5a siRNA (hMSC siRNA Wnt5a and PreOB siRNA Wnt5a) in comparison with the control siRNA (hMSC siRNA Cy and PreOB siRNA Cy) (Figure 5a ). Qualitative PCR showed that Wnt5a silencing reduced the expression of the osteogenic markers ALP, COL1A1 and OC mRNA (Figure 5b) , and real-time PCR confirmed the reduction in ALP mRNA levels induced by siRNA anti-Wnt5a in PreOB cells (Figure 5c ). þ cells of a representative MM patient (d). Graphs show the optical density (OD) ratio of P-PKC normalized for the internal control actin in both HOB-01 and PreOB (e). NFATc1 activity was evaluated using an ELISA-based method according to manufacturer's procedures. The graph ± bars indicate the mean normalized OD related to NFATC1 activity ( ± s.d.) (*P ¼ 0.05). ROCK activity in the cytoplasm was evaluated as described in Materials and methods. The graph±bars show the mean OD related to ROCK activity (±s.d.) (*Po0.05) (f ). Figure 3 . Wnt5a treatment activates the non-canonical Wnt pathway in human BM mesenchymal cells, and increases their osteogenic properties by counterbalancing the inhibitory effect of myeloma cells. The human BM stromal cell line was treated with rmWnt5a at different concentrations (100-500 ng/ml). Intracellular calcium-influx was evaluated by means of flow cytometry after 20 min of treatment using the fluorescent calcium indicator Fluo-4AM (Molecular Probes, Invitrogen) (a). P-PKC and calcineurin expression was evaluated in HS-5 after 20 min of treatment with rmWnt5a at 200 and 500 ng/ml (b). NFATc1 and ROCK activity was checked after 2 h: the graph ± bars represent mean optical density (±s.d.) (*Po0.05) (c). Evaluation of ALP þ CFU-F, and bone nodule formation as indicated by alizarin red staining, in human BM mononuclear cells seeded in osteogenic differentiation medium in the presence of rmWnt5a (500 ng/ml), rmWnt3a (500 ng/ml) or vehicle for 2-3 weeks. The graph±bars indicate the mean number of ALP þ CFU-F and bone nodules (±s.d.) (*Po0.05) (d). Human BM mononuclear cells were co-cultured with XG-1 or primary purified CD138 þ for 2-3 weeks in osteogenic differentiation medium, in a transwell insert in the presence or absence of rmWnt5a (500 ng/ml) or rmWnt3a (500 ng/ml). Media was replaced every 3 days. At the end of culture period, ALP þ CFU-F (e) and bone nodules (f ) were quantified as described in the Materials and methods. The photographs show the ALP (e) and alizarin red staining (f ) of a representative experiment (original magnification Â 1). The graph ± bars indicate the mean number of ALP þ CFU-F and bone nodules (±s.d.) per well (*Po0.05) (e and f ).
Ror2 overexpression induced by a lentiviral vector in hMSCs increases their osteogenic properties and counterbalances the inhibitory effect of HMCLs As we found that both HMCLs and primary CD138 þ MM cells inhibit the expression of the Ror2 co-receptor of non-canonical Wnt5a Wnt signaling in hMSCs differentiated towards PreOB, we next investigated the effect of Ror2 overexpression on the osteogenic properties of hMSCs in the presence of HMCLs. We first enforced Ror2 expression using a lentiviral vector in HOB-01 PreOB cells, HS-5 BM mesenchymal stromal cells, and primary hMSCs. The efficiency and efficacy of cell transduction were, respectively, evaluated by means of flow cytometry and real-time PCR (Figure 6a) . Consistent with the Ror2 overexpression, an increase in P-PKC protein levels and a decrease in b-catenin levels were observed, supporting the activation of the non-canonical pathway and the inhibition of the canonical pathway (Figure 6b) .
We then investigated the effect of primary hMSC Ror2 overexpression on osteogenic differentiation towards PreOB cells, and found that ALP staining was significantly greater in PreOB-Ror2 than in PreOB-pWPI cells in osteogenic differentiation medium (Figure 6c ). In line with this, the expression of the osteogenic markers ALP and COL1A1 mRNA was higher in PreOB-Ror2 than in PreOB-pWPI cells (Figures 6d and e) . Finally, the stimulatory effect on ALP and COL1A1 mRNA expression level was also maintained in the co-culture system with HMCLs, as shown for XG-1 in the presence or absence of a transwell insert (Figure 6e ).
DISCUSSION
The non-canonical Wnt pathway acts in a b-catenin-independent manner as Wnt only binds to the FZD receptor and not to the LRP 5/6 co-receptor. 18, 19 The signal transduction of non-canonical Wnt activators also requires the presence of co-receptors such as Ror2. 26 The most widely known routes of non-canonical signaling are the planar cell polarity pathway and the Wnt/Ca þ þ signaling pathway. 18, 19 The planar cell polarity signal is transduced by the RhoA-ROCK pathway and the small GTPases RAC1, which activates JNK signaling, whereas the Wnt/Ca þ þ signal leads to the activation of PKC, and an increase in intracellular Ca þ þ and NFATc1 activation. 18, 19 It has recently been shown that activation of the non-canonical signal pathway by Wnt5a rather than activation of the canonical pathway by Wnt3a stimulates more differentiated osteoblast CFU-OB precursors in human BM cultures, 21, 22 and that the pro-osteogenic effect of Wnt5a is mediated by the activation of Ror2 receptors. 26 These data suggest that the non-canonical signal pathway may have a role in the osteogenic differentiation of hMSCs.
On the basis of these findings, we first investigated the expression of canonical and non-canonical Wnt signaling activators, receptors and inhibitors in hMSCs, and the impact of osteogenic differentiation on their expression. Our data indicate that non-canonical rather than canonical Wnt signaling is activated in hMSCs, because the hMSCs expressed the Wnt5a activator of the non-canonical Wnt pathway, but not the Wnt3a activator of the canonical pathway, and do express the canonical inhibitor Dkk-1. We also found that osteogenic differentiation induced an increase in the expression of both FZD5 and Ror2 in hMSCs, suggesting that osteogenic differentiation is accompanied by the overexpression of the receptor and co-receptor systems of the non-canonical Wnt pathway, together with an overexpression of the inhibitor of Wnt canonical signaling FRZB. Interestingly, the critical role of the co-receptor Ror2 in osteoblast formation has recently been underlined. 28, 29 Furthermore, we demonstrated that Ror2 mRNA expression was lower in both hMSC and PreOB from MM patients than those obtained from healthy controls, suggesting a critical role of Ror2 in the pathophysiology of osteoblast suppression in MM.
Thus, on the basis of our experimental evidence and published findings, we investigated the potential effect of both HMCLs and primary CD138
þ MM cells on the non-canonical Wnt signaling pathway in PreOB cells, and found that they inhibit FZD5 and Ror2 expression in both human BM PreOB cells and HOB-01 cells in coculture systems, and also inhibit P-PKC expression and NFATc1 and ROCK activity. This suggests that HMCLs and primary CD138 þ MM cells inhibit the non-canonical Wnt signaling pathway in PreOB cells, including the Wnt5a/Ca þ þ /PKC and Wnt5a/Ror2 transduction pathways, thus inhibiting the activity of both NFATc1 and ROCK. We have previously found that HMCLs do not inhibit the expression and nuclear translocation of b-catenin in human BM PreOB cells in the same co-culture systems despite their production of canonical Wnt inhibitors such as Dkk-1 and sFRP-3, 15 though it has been previously reported that primary CD138 þ MM cells inhibit canonical Wnt signaling in murine pluripotential MSCs. 13, 15 Interestingly recent data show that SFRP-3 produced by HMCLs stimulate canonical Wnt signaling in PreOB cells, in contrast to Dkk-1, and increases the level of active b-catenin 30 indicating that the lack of effect of MM cells on canonical Wnt signaling in BM opsteoprogenitor cells could be due to the opposing effects of Dkk-1 and sFRP-3 both produced by MM cells. Overall our evidence and that of others suggests that HMCLs and primary CD138 þ MM cells inhibit non-canonical rather than canonical Wnt signaling in human BM PreOB cells.
Interestingly, the inhibitory effect of HMCLs on the non-canonical Wnt signal pathway in human PreOB cells was observed regardless of their production of Wnt5a, as it was found in Wnt5a-negative and Wnt5a þ HMCLs. This is not surprising as the level of Wnt5a produced by HMCLs such as KMS27 is low; o500 ng/ml, which stimulates non-canonical Wnt5a signaling and osteogenic differentiation in PreOB cells. Furthermore, we failed to find a relationship between Wnt5a expression in primary CD138
þ MM cells and the presence of osteolytic bone lesions in a large cohort of MM patients. Taken together, these findings suggest that Wnt5a production by MM cells is not involved in inhibiting osteogenic differentiation in a paracrine fashion.
The capacity of HMCLs and primary CD138
þ MM cells to inhibit Ror2 expression and the non-canonical Wnt signaling pathway in human PreOB cells was observed in the presence and absence of a transwell insert, as we have previously reported in the case of Runx2 activity. 3 This suggests that both soluble factors and cell contacts may be involved in these effects. Interestingly, it has been reported that the Runx2 and Wnt5a/Ror2 pathways have a cooperative rather than a direct relationship in controlling osteoblastogenesis, 31, 32 which supports the hypothesis that both systems are probably involved in the MM-induced suppression of the osteogenic differentiation of hMSCs.
Interleukin-7 has previously been identified as a possible soluble factor involved in the MM-induced inhibition of Runx2 and blockade of osteogenic differentiation, 3, 33 but there is no evidence concerning its involvement in suppressing the noncanonical signal pathway. Further studies are therefore necessary to identify the soluble factors involved in the MM-induced inhibition of the non-canonical Wnt signaling pathway in human PreOB cells, especially as it has been found that HMCLs and primary CD138
þ MM cells do not express inhibitors of the noncanonical Wnt pathway such as sFRP-1, 15 but may produce inhibitors of the canonical pathway, such as DKK-1, sFRP-2 and sFRP-3.
13,15,34
As we found that HMCLs and primary CD138 þ MM cells inhibit Ror2 and the non-canonical Wnt5a signaling pathway in human BM PreOB cells, we next investigated whether activation of the non-canonical pathway can stimulate osteogenic differentiation in hMSCs and blunt the inhibitory effect of MM cells. Several approaches were used: (i) stimulation with recombinant Wnt5a treatment; (ii) enforced Wnt5a expression by lentiviral vectors; and (iii) enforced Ror2 expression by lentiviral vectors. Treatment with Wnt5a activated the non-canonical pathway and increased both CFU-F and CFU-OB formation in BM cultures and, more importantly, blunted the inhibitory effect of HMCLs and primary CD138 þ MM cells. In contrast, Wnt3a treatment did not led to any changes in ALP expression or bone nodule formation, and did not block the suppressive effect of HMCLs and primary CD138 þ MM cells on CFU-F and CFU-OB in co-cultures. Accordingly, it has been reported by others that Wnt5a stimulates more differentiated CFU-OB osteoblast precursors in human BM cultures, 21, 22 whereas stimulation with canonical Wnt3a increases the proliferation of early undifferentiated mesenchymal progenitor cells but inhibits their osteogenic differentiation. 16, 17 Secondly, we induced Wnt5a overexpression by a lentiviral vector in BM stromal cell lines and primary BM hMSCs from MM patients, and found that Wnt5a overexpression increased the levels of active P-PKC and NFATc1 and ROCK activity, thus demonstrating the activation of the non-canonical Wnt pathway. Interestingly, Wnt5a overexpression decreased the level of b-catenin, the main component of the canonical pathway, suggesting that Wnt5a inhibits canonical signaling and the presence of regulatory cross-talk between the canonical and non-canonical pathways. In line with this hypothesis, it has been previously reported that the canonical and non-canonical Wnt pathways have an antagonistic relationship insofar as Wnt5a inhibits the effects of Wnt3a on MSCs, whereas Wnt3a suppresses the Wnt5a-mediated enhancement of osteogenesis. 21, 22 We found that Wnt5a overexpression stimulates the osteogenic capacity of primary hMSCs by increasing ALP expression and bone nodule formation, and that Wnt5a suppression by siRNA inhibits the expression of osteogenic markers.
The overexpression of Wnt5a in hMSCs also blunted the inhibitory effect of HMCLs on the expression of osteogenic markers in co-cultures. In line with our findings, others have demonstrated that non-canonical Wnt-4 overexpression in MSCs enhances the osteogenic differentiation of MSCs in vitro and bone formation in vivo. 23 Taken together, these findings suggest that that Wnt5a-mediated non-canonical Wnt pathway is a potential target for stimulating the osteogenic and bone regenerative properties of human MSCs. Accordingly, it has been reported that anabolic agents, such as strontium ranelate, stimulate osteoblast differentiation by activating NFAT-mediated non-canonical Wnt signaling. 35 Interestingly, by means of gene expression profiling analysis on GeneChip HG-U133Plus2.0 arrays, we also found that Wnt5a or Ror2 overexpression mediated by lentiviral vectors upregulated several chemokines, including CXCL10 and CXCL11 (Agnelli L et al., unpublished data) that are known to be involved in osteoblast differentiation 36 and in the inhibition of osteoclastogenesis. 37 Similarly, recently published data indicated that treatment of osteoblasts with Wnt5a induces the production of several chemokines involved in the regulation of inflammatory and bone remodeling processes. 38 Finally, on the basis of published findings indicating that the Ror2 receptor has a critical role in osteoblastogenesis, 28, 29 and our findings that the osteogenic differentiation of hMSCs towards PreOB cells increases Ror2 expression while HMCLs and primary CD138 þ MM cells have an inhibitory effect, we overexpressed Ror2 in hMSCs. Interestingly, Ror2 overexpression in stromal cell lines and PreOB cells, as well as in primary hMSCs, activated the non-canonical Wnt pathway and inhibited the canonical pathway (and consequently the expression of osteogenic markers) even in the presence of co-cultured MM cells. These results support the pathophysiological role of Ror2 in the MM-induced inhibition of osteogenic differentiation and further suggest that non-canonical Wnt signaling in hMSCs may be a therapeutic target for increasing their osteogenic properties in MM-related bone disease.
